Preclinical
Shares of Protagonist Therapeutics climbed nearly 4% in premarket trading after the company announced its lead drug candidate rusfertide snagged Breakthrough Therapy Designation from the U.S. FDA.
The nation’s top science adviser believes the country’s renewed enthusiasm for science may pave the way for plug-and-play vaccines that can nullify the next pandemic before it starts.
The new approval for Cosentyx marks the first for a pediatric patient population in the U.S. Here’s everything you need to know about this new drug from Novartis.
Researchers at multiple companies and institutes are doggedly pursuing clinical programs so the virus can become little more than a hindrance in the future.
Sanofi said that the phase II/III trial studying venglustat in autosomal dominant polycystic kidney disease was scrapped because it “did not meet futility criteria.”
The newly approved drug, Lybalvi, is a once-daily oral antipsychotic drug that is both a maintenance monotherapy or for the acute treatment of manic or mixed episodes.
Amgen reunites with Kyowa Kirin on the development and potential commercialization of KHK4083, an atopic dermatitis drug, which impacts nearly 30 million people worldwide.
The FDA gave the green light to Amgen’s Lumakras under accelerated approval as a treatment for patients with KRAS mutation whose disease has worsened over time.
The question before the committee was whether the benefits of teplizumab outweigh the risks as it voted 10-7 in favor of the drug to delay clinical type 1 diabetes mellitus.
Fennec is looking for a second chance to approve PEDMARK, its pediatric chemotherapy-induced hearing loss prevention drug, as it resubmits its NDA for the agent to the U.S. FDA.
PRESS RELEASES